The diagnosis of hepatic fibrosis by magnetic resonance and near-infrared imaging using dual-modality nanoparticles

Hepatic fibrosis (HF), as the only reversible process of chronic liver disease, remains a big diagnostic challenge. Development of noninvasive and effective methods to assess quantitatively early-stage HF is of great clinical importance. Compared with conventional diagnostic methods, near-infrared f...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yunfang, Shang, Wenting, Liang, Xiaoyuan, Zeng, Chaoting, Liu, Mingming, Wang, Sudan, Li, Hongjun, Tian, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078292/
https://www.ncbi.nlm.nih.gov/pubmed/35540380
http://dx.doi.org/10.1039/c7ra10847h
_version_ 1784702297575522304
author Li, Yunfang
Shang, Wenting
Liang, Xiaoyuan
Zeng, Chaoting
Liu, Mingming
Wang, Sudan
Li, Hongjun
Tian, Jie
author_facet Li, Yunfang
Shang, Wenting
Liang, Xiaoyuan
Zeng, Chaoting
Liu, Mingming
Wang, Sudan
Li, Hongjun
Tian, Jie
author_sort Li, Yunfang
collection PubMed
description Hepatic fibrosis (HF), as the only reversible process of chronic liver disease, remains a big diagnostic challenge. Development of noninvasive and effective methods to assess quantitatively early-stage HF is of great clinical importance. Compared with conventional diagnostic methods, near-infrared fluorescence imaging (NIR) and magnetic resonance imaging (MRI) could offer highly sensitive and spatial resolution signals for HF detection. However, precise detection using contrast agents is not possible. Superparamagnetic iron oxide (SPIO) nanoparticles have low toxicity, high sensitivity and excellent biocompatibility. Integration of Fe(3)O(4) nanoparticles and indocyanine green (ICG), coupled with targeting ligand of integrin α(v)β(3), arginine–glycine–aspartic acid (RGD) expressed on hepatic stellate cells (HSCs), were used to detect HF. Both in vivo and in vitro results showed that the SPIO@SiO(2)–ICG–RGD had high stability and low cytotoxicity. The biodistribution of SPIO@SiO(2)–ICG–RGD was significantly different between mice with HF and healthy controls. SPIO@SiO(2)–ICG–RGD was characterized and the results of imaging in vitro and in vivo demonstrated the expression of integrin α(v)β(3) on activated HSCs. These data suggest that our SPIO@SiO(2)–ICG–RGD probe could be used for the diagnosis of early-stage HF. This new nanoprobe with a dual-modality imaging approach holds great potential for the diagnosis and classification of HF.
format Online
Article
Text
id pubmed-9078292
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-90782922022-05-09 The diagnosis of hepatic fibrosis by magnetic resonance and near-infrared imaging using dual-modality nanoparticles Li, Yunfang Shang, Wenting Liang, Xiaoyuan Zeng, Chaoting Liu, Mingming Wang, Sudan Li, Hongjun Tian, Jie RSC Adv Chemistry Hepatic fibrosis (HF), as the only reversible process of chronic liver disease, remains a big diagnostic challenge. Development of noninvasive and effective methods to assess quantitatively early-stage HF is of great clinical importance. Compared with conventional diagnostic methods, near-infrared fluorescence imaging (NIR) and magnetic resonance imaging (MRI) could offer highly sensitive and spatial resolution signals for HF detection. However, precise detection using contrast agents is not possible. Superparamagnetic iron oxide (SPIO) nanoparticles have low toxicity, high sensitivity and excellent biocompatibility. Integration of Fe(3)O(4) nanoparticles and indocyanine green (ICG), coupled with targeting ligand of integrin α(v)β(3), arginine–glycine–aspartic acid (RGD) expressed on hepatic stellate cells (HSCs), were used to detect HF. Both in vivo and in vitro results showed that the SPIO@SiO(2)–ICG–RGD had high stability and low cytotoxicity. The biodistribution of SPIO@SiO(2)–ICG–RGD was significantly different between mice with HF and healthy controls. SPIO@SiO(2)–ICG–RGD was characterized and the results of imaging in vitro and in vivo demonstrated the expression of integrin α(v)β(3) on activated HSCs. These data suggest that our SPIO@SiO(2)–ICG–RGD probe could be used for the diagnosis of early-stage HF. This new nanoprobe with a dual-modality imaging approach holds great potential for the diagnosis and classification of HF. The Royal Society of Chemistry 2018-02-12 /pmc/articles/PMC9078292/ /pubmed/35540380 http://dx.doi.org/10.1039/c7ra10847h Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/
spellingShingle Chemistry
Li, Yunfang
Shang, Wenting
Liang, Xiaoyuan
Zeng, Chaoting
Liu, Mingming
Wang, Sudan
Li, Hongjun
Tian, Jie
The diagnosis of hepatic fibrosis by magnetic resonance and near-infrared imaging using dual-modality nanoparticles
title The diagnosis of hepatic fibrosis by magnetic resonance and near-infrared imaging using dual-modality nanoparticles
title_full The diagnosis of hepatic fibrosis by magnetic resonance and near-infrared imaging using dual-modality nanoparticles
title_fullStr The diagnosis of hepatic fibrosis by magnetic resonance and near-infrared imaging using dual-modality nanoparticles
title_full_unstemmed The diagnosis of hepatic fibrosis by magnetic resonance and near-infrared imaging using dual-modality nanoparticles
title_short The diagnosis of hepatic fibrosis by magnetic resonance and near-infrared imaging using dual-modality nanoparticles
title_sort diagnosis of hepatic fibrosis by magnetic resonance and near-infrared imaging using dual-modality nanoparticles
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078292/
https://www.ncbi.nlm.nih.gov/pubmed/35540380
http://dx.doi.org/10.1039/c7ra10847h
work_keys_str_mv AT liyunfang thediagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles
AT shangwenting thediagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles
AT liangxiaoyuan thediagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles
AT zengchaoting thediagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles
AT liumingming thediagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles
AT wangsudan thediagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles
AT lihongjun thediagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles
AT tianjie thediagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles
AT liyunfang diagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles
AT shangwenting diagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles
AT liangxiaoyuan diagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles
AT zengchaoting diagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles
AT liumingming diagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles
AT wangsudan diagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles
AT lihongjun diagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles
AT tianjie diagnosisofhepaticfibrosisbymagneticresonanceandnearinfraredimagingusingdualmodalitynanoparticles